A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)-Reference-Cited by-同舟云学术

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)

Published:2023-11 Issue: Volume:193 Page:113312
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kim Kyoo Hyun^ORCID,Jung Minkyu,Lee Hyo Jin,Lee Su Jin,Kim Miso,Ahn Mi Sun,Choi Moon Young,Lee Na-Ri,Shin Sang Joon

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond;Gershenwald;Ann Surg Oncol,2018

2. Managing metastatic melanoma in 2022: a clinical review;Switzer;JCO Oncol Pract,2022

3. KIT as a therapeutic target in metastatic melanoma;Carvajal;JAMA J Am Med Assoc,2011

4. KIT amplification and gene mutations in acral/mucosal melanoma in Korea;Yun;APMIS,2011

5. Large-scale analysis of KIT aberrations in Chinese patients with melanoma;Kong;Clin Cancer Res,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib in patients with pretreated advanced melanoma: a single-center case series;Melanoma Research;2024-05-27

2. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma;Expert Opinion on Pharmacotherapy;2024-03-23

3. Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma;The Oncologist;2024-03-12